clinical trial · NCT06382987
A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
Bristol-Myers Squibb·—·recruiting·n = 600
Plaque PsoriasisDeucravacitinibApremilast
brief summary
This is a prospective, observational, real-world study of adult participants in Japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.
started
Jan 22, 2024
primary completion
Dec 31, 2029
completion
Dec 31, 2029
last updated
Apr 25, 2024
official title
Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-World, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol